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Abstract—A series of two classes of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates were synthesized using click chemistry 
approach. All compounds were evaluated for inhibition of Src kinase and human ovarian adenocarcinoma (SK-Ov-3), breast carcinoma 
(MDA-MB-361), and colon adenocarcinoma (HT-29). Hexyl triazolyl-substituted 3-phenylpyrazolopyrimidine exhibited inhibition of Src 
kinase with an IC50 value of 5.6 µM. 4-Methoxyphenyl triazolyl-substituted 3-phenylpyrazolopyrimidine inhibited the cell proliferation of 
HT-29 and SK-Ov-3 by 73% and 58%, respectively, at a concentration of 50 µM. 
Phosphorylation of many protein substrates occurs 
in the presence of protein tyrosine kinases (PTKs) that 
catalyze the transfer of γ-phosphate group from ATP to 
specific tyrosine residues. PTKs have critical roles in 
the signal transduction pathways. Src family kinases 
(SFKs) are a family of nine different PTKs, including c-
Src, c-Yes, Fyn, Lck, Lyn, Hck, Frk, Blk, and c-Fgr of 
which Src is the prototype.1 SFKs have important roles 
in the regulation of a wide variety of normal cellular 
signal transduction pathways, such as cell division, 
growth factor signaling, differentiation, survival, 
adhesion, migration, and invasion.2 Src tyrosine kinase 
expression is frequently elevated in a number of 
epithelial tumors including colon, breast, prostate, lung, 
ovary, and pancreas compared with the adjacent normal 
tissues. Src kinase is a key modulator of cancer cell 
invasion and metastasis.3-6 
In recent years development of Src kinase inhibitors 
for the treatment of cancer is a subject of major interest.7 
A number of inhibitors of protein kinases8 such as 
quinazolines,9 quinolinecarbonitriles,10 
pyrazolopyrimidines,11 imidazo[1,5-a]pyrazines,12 
benzotriazines,13 ATP−phosphopeptide conjugates,14 
pyrimidoquinolines,15 and pyridopyrimidinones16, have 
been investigated for the treatment of cancer, chronic 
inflammatory diseases, and other indications.17 Imatinib 
is a 2-phenylaminopyrimidine nonselective PTK 
inhibitor of ABL, c-Kit, and PDGFR approved for the 
treatment of a number of malignancies like chronic 
myelogenous leukemia (CML) and gastrointestinal 
stromal tumors (GISTs).18 However, various imatinib-
resistant mutations are generated spontaneously on Abl 
over long-term course of treatment.19 Dasatinib (BMS-
354825) is a pyrimidinylthiazole-based ATP-
competitive dual SRC/ABL inhibitor20 approved to use 
in patients with CML after imatinib treatment. 
Bosutinib (SKI-606), a 3-quinolinecarbonitrile-based 
Src kinase inhibitor, is known to suppress migration and 
invasion of human breast cancer cells.21 
Crystallographic studies of an ATP mimic, 
AMP−PNP, bound to c-Src (PDB 2SRC)22 and 
complexes of 3-phenylpyrazolopyrimidine derivatives 
(PP1 and PP2) (Fig. 1) as ATP-binding site inhibitors 
with Hck (PDB 1QCF)23 and Lck (PDB 1QPE)24 have 
revealed that the pyrazolopyrimidine core of PP1 and 
PP2 mimic the adenine base of ATP in binding to the 
nucleotide binding site. We have previously shown that 
3-phenyl group contributes significantly to Src kinase 
inhibitory activity through a hydrophobic interaction 
with a large hydrophobic pocket in the ATP-binding 
site.25a Another cavity is formed from side chains of 
helix αC and helix αD. This cavity is normally occupied 
 by carbohydrate moiety followed by triphosphate group 
of ATP and remains mostly unfilled by tert-butyl of 3-
phenylpyrazolopyrimidines (PP1 and PP2). 
In continuation of our efforts to design or identify new 
Src kinase inhibitors,14,25 we investigated whether that 
variation of N1 substitution in 3-
phenylpyrazolopyrimidines with different 1,2,3-
triazoles containing hydrophobic residues can occupy 
and/or interact with amino acids of this cavity and 
contribute to the enhancement of Src kinase inhibitory 
potency. Herein, we describe synthesis and evaluation 
of Src kinase inhibitory activity of two classes of 3-
phenylpyrazolopyrimidine (PhPP)-1,2,3-traizole 
conjugates (Fig. 1), in which the pyrazolo ring of PhPP 
is attached through an ethylene or a methylene linker to 
positions 1 and 4 of the triazole, respectively. All the 
compounds were synthesized under click reaction 
conditions. 
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Figure 1. Chemical structures of 3-phenylpyrazolopyrimidines and 1,4-
disubstituted 1,2,3-triazoles. 
 
Synthesis of PhPP scaffolds (7a−b) was achieved 
according to the previously reported procedure with 
slight modification as shown in Scheme 1.25,26 2-
Benzoylmalononitrile (3) was synthesized from the 
reaction of benzoyl chloride (1) with malononitrile (2) 
in the presence of sodium hydride in THF. Methylation 
of 3 with dimethyl sulfate in the presence of sodium 
bicarbonate in dioxane afforded 2-
(methoxyphenylmethylene)malononitrile (4), which was 
cyclized by treatment with hydrazine hydrochloride or 
2-hydroxyethyl hydrazine in the presence of 
triethylamine to afford 5-amino-3-phenyl-1H-pyrazole-
4-carbonitrile (6a) or 5-amino-1-(2-hydroxyethyl)-3-
phenyl-1H-pyrazole-4-carbonitrile (6b), respectively. 
Reaction of (6a−b) with formamide at 180 °C for 24 h 
afforded the corresponding PhPP scaffolds 7a and 7b in 
72 and 76% yields, respectively. 
 
 
Scheme 1. Synthesis of N1-substituted PhPP scaffolds. 
 
Compounds 7b and 7a were used for the synthesis 
of azido- and alkyne-substituted building blocks 9 and 
12, respectively, needed for click reactions. Synthesis of 
compound 9 was carried out by mesylation of 7b 
followed by nucleophilic substitution with sodium azide 
in DMF (Scheme 2). Compound 12 was prepared by the 
reaction of 7a with propargyl bromide in the presence of 
potassium carbonate in acetone at room temperature 
(Scheme 3). Only the N1-endocyclic amino group of 
PhPP derivatives was reacted with propargyl bromide. 
Unprotected N4-exocyclic amine was not reactive under 
these reaction conditions as shown previously.27 
Two classes of PhPP-1,2,3-triazole conjugates 
(11a−i and 14a−j) were prepared by the click chemistry 
approach using regioselective addition of 9 with 
different alkynes (10a−i) (Scheme 2) and 12 with 
different azides (13a−k) (Scheme 3) catalyzed by in situ 
generated copper(I) salt at room temperature. The 
reactions proceeded in high yields (76-88%) and in a 
regioselective manner. All the compounds were purified 
using column chromatography and characterized by 1H 
NMR, 13C NMR, and HRMS spectroscopy. The IR 
spectra of the compounds (14a−j) exhibited a strong 
band at about 1685 cm-1 confirming the presence of a 
carbonyl group. In 1H NMR spectra of 11a−i and 14a−j 
a characteristic singlet was observed for triazolyl C5-H 
at about δ 7.90 ppm. 
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Scheme 2. Synthesis of PhPP-1,2,3-triazole conjugates 11a−i. 
 
 
 
Scheme 3. Synthesis of PhPP-1,2,3-triazole conjugates 14a−j. 
 
An array of 20 diversely substituted PhPP-1,2,3-
triazole conjugates were evaluated against Src kinase. 
The results of Src kinase inhibitory activity of 
compounds in classes 1 (11a−i) and 2 (14a−j) are 
shown in Tables 1 and 2, respectively. 
 All compounds in class 1 showed less inhibitory 
activities when compared with that of PP2. A number of 
compounds 11b, 11f, and 11g showed modest inhibitory 
activity (IC50 = 5.6−29.6 µM) (Table 1). These data 
suggest that the presence of 1,2,3-triazole-substituted 
with bulky groups and attached through an ethylene to 
PhPP scaffold is less tolerated, possibly because the 
cavity cannot accommodate large groups. Furthermore, 
the substitutions may not be oriented appropriately in 
the cavity or may have unfavorable interactions. 
 
Table 1. The Src kinase inhibitory activities of compounds 11a−i (class 
1). 
 
Compds R IC50 (µM)a Log P (Calcd)c 
  
  
9 - 6.2 - 
11a CH3(CH2)2CH2- >75 2.83 
11b CH3(CH2)4CH2- 5.6 3.89 
11c CH3(CH2)5CH2- >75 4.41 
11d CH3(CH2)8CH2- >75 5.47 
11e C6H5CH2- NA
b
 2.81 
11f 4-CH3OC6H4- 17.4 3.06 
11g 4-FC6H4- 29.6 3.25 
11h 4-CH3COC6H4- >75 2.60 
11i -CH2CH2CH2Cl NA 2.01 
Staurosporine - 0.3  - 
PP2 - 2.8  3.57 
aThe concentration that inhibited enzyme activity by 50%; bless than 10% 
enzyme inhibitory activity was observed up to the concentration of 250 
µM; cCalculated partition coefficient using ChemBioDraw Ultra 12.0. 
 
Compounds in class 2 exhibited more diverse 
inhibitory activities (Table 2). Compounds 14e, 14f, 14i, 
and 14j demonstrated modest Src inhibitory activities 
with IC50 values between 9.1 and 23.1 µM. 1,2,3-
Triazole-substituted with naphthyl (14h), tolyl (14c), 
and 4-chlorophenyl (14a and 14g) showed significantly 
weak inhibitory potency, suggesting incorporation of 
bulky groups are less tolerated in the cavity. The 
presence of 1,2,3-triazole between PhPP scaffold and 
the substitution through a carbonyl group provides less 
flexibility for the substituted moieties at N1 position to 
be accommodated into cavity. 
Molecular modeling and minimization was used to 
explore how the structures would fit within the ATP-
binding site of the enzyme (Fig. 2). The modeling 
studies indicated that phenyl groups in 11b and 14f 
occupy the hydrophobic binding pocket similar to tolyl 
group of PP1 with slightly different orientations (Fig. 
2). In case of 11b, the flexible hexyl group is oriented 
towards the hydrophobic pocket possibly because of 
favorable hydrophobic interactions. On the other hand, 
the fluorophenyl group in 14f is positioned towards the 
large cavity where the triphosphate group of ATP 
usually binds similar to that of t-butyl group of PP1, 
possibly because the amide moiety in 14f does not allow 
flexibility seen in 11b. 
 
Table 2. The Src kinase inhibitory activities of compounds 14a−j (class 
2). 
 
Compds R IC50 (µM)a Log P (Calcd)c 
  
  
14a 4-Cl-C6H4- >75 2.89 
14b C6H5- >75 2.11 
14c 4-CH3C6H5- >75 2.60 
14d 
 
>75 1.88 
14e 
 
23.1 1.82 
14f 
 
16.4 2.22 
14g 
 
>75 2.79 
14h 
 
NAb 3.83 
14i -CH2CH2CH2OH 9.1 0.32 
14j CH3CH2O- 12.7 1.35 
Staurosporine - 0.3   
PP2 - 2.8   
aThe concentration that inhibited enzyme activity by 50%; bless than 10% 
enzyme inhibitory activity was observed up to the concentration of 250 
µM; cCalculated partition coefficient using ChemBioDraw Ultra 12.0. 
 
 
 
Figure 2. Comparison of structural complexes of Src kinase with 
different PhPP derivatives. 11b (green), PP1 (blue), and (b) 14f (red)) 
based on molecular modeling. The compounds and side chains of amino 
acids are rendered in stick styles. Compounds are in the lowest energy 
conformers predicted. The Figure is drawn using the Accelrys 
visualization system. 
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Figure 3. Inhibition of HT-29, MDA-MB-361, and SK-Ov-3 cell proliferation by compounds 11a-i and 14a-j (50 µM) after 72 h incubation. The results 
are shown as the percentage of the control DMSO that has no compound (set at 100%). All the experiments were performed in triplicate. 
 
The effect of the inhibitors at the concentration of 
50 µM on the cell proliferation of cancer cells that 
overexpress c-Src was also evaluated against human 
ovarian adenocarcinoma cells (SK-Ov-3), breast 
carcinoma (MDA-MB-361), and colon 
adenocarcinoma (HT-29) cell lines (Fig. 3). All three 
cell lines express highly activated Src.28,29 Compounds 
11f and 11i inhibited the cell proliferation of colon 
cancer cells (HT-29) by 73% and 57%, respectively, 
(Figure 3) whereas compounds 11f and 14h inhibited 
the growth of ovarian cancer cells (SK-Ov-3) by 
approximately 58% and 48%, respectively (Fig. 3). 
Compounds 11g and 14e were able to inhibit the cell 
proliferation of breast cancer cells (MDA-MB-361) by 
49% and 51%, respectively (Fig. 3). 
There were some correlation between Src kinase 
inhibitory potency of the compounds and the growth 
inhibition of cancer cells since compounds 11f, 11g, 
14e, and 14f were modest Src kinase inhibitors. The 
data suggest that modest Src inhibition may lead to 
anticancer activities of these compounds, but this 
correlation is not always perfect possibly because of the 
diversity in solubility (see calculated Log P values in 
Tables 1 and 2) and cellular uptake of these compounds 
in these cell lines as 11b a modest Src kinase inhibitor 
was not a potent inhibitor of cell proliferation. 
In summary, compounds 11b and 14i exhibited 
modest inhibitory potency (IC50 = 5.6−9.1 µM) against 
Src kinase. Structure−activity relationship studies 
suggested that the incorporation of bulky groups at N1 
position of PhPP is less tolerated. 4-Methoxyphenyl 
triazolyl-substituted 3-phenylpyrazolo-pyrimidine (11f) 
inhibited the cell proliferation of HT-29 by 73% at a 
concentration of 50 µM. The data provide insights for 
further optimization of these compounds as Src kinase 
inhibitors and/or anticancer agents. 
 
Acknowledgments 
We acknowledge Department of Science and 
Technology, New Delhi Project # SR-FTP-CS-34-2007, 
the American Cancer Society Grant # RSG-07-290-01-
CDD, and National Science Foundation, Grant Number 
CHE 0748555 for the financial support. 
 
Supplementary data 
Supplementary data including experimental 
procedures and characterization of compounds can be 
found in the online version of this article. 
 
References 
1 Yeatman, T. J. Nat. Rev. Cancer 2004, 4, 470. 
2 Summy J. M.; Gallick, G. E. Cancer Metastasis 
Rev. 2003, 22, 337. 
3 Frame, M. C. Biochim. Biophys. Acta 2002, 1602, 
114.  
4 (a) Irby, R. B.; Yeatman, T. J. Oncogene, 2000, 19, 
5636. (b) Summy, J. M.; Gallick, G. E. Clin. 
Cancer Res. 2006, 12, 1398. 
5 Biscardi, J. S.; Ishizawar, R. C.; Silva, C. M.; 
Parsons, S. J. Breast Cancer Res. 2000, 2, 203. 
6 Fizazi, K. Ann. Oncol. 2007, 18, 1765. 
 7 Cohen, P. Nat. Rev. Drug Disc. 2002, 1, 309. 
8 (a) Ye, G.; Tiwari, R.; Parang, K. Curr. Opin. 
Investig. Drugs 2008, 9, 605. (b) Parang, K.; Sun, 
G. Expert Opin. Ther. Patents, 2005, 15, 1183. 
9 (a) de Vries, T. J.; Mullender, M. G.; van Duin, M. 
A.; Semeins, C. M.; James, N.; Green, T. P.; Everts, 
V.; Klein-Nulend, J. Mol. Cancer Res. 2009, 7, 476. 
(b) Plé, P. A.; Green, T. P.; Hennequin, L. F.; 
Curwen, J.; Fennell, M.; Allen, J.; Brempt, C. L.; 
Costello, G. J. Med. Chem. 2004, 47, 871. 
10 Tsou, H. R.; Overbeek-Klumpers, E. G.; Hallett, W. 
A.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; 
Michalak, R. S.; Nilakantan, R.; Discafani, C.; 
Golas, J.; Rabindran, S. K.; Shen, R.; Shi, X.; 
Wang, Y. F.; Upeslacis, J.; Wissner, A. J. Med. 
Chem. 2005, 48, 1107.  
11 Hanke, J. H.; Gardner, J. P.; Dow, R. L.; 
Changelian, P. S.; Brissette, W. H.; Weringer, E. J.; 
Pollok, B. A.; Connelly, P. A. J. Biol. Chem. 1996, 
271, 695. 
12 (a) Mukaiyama, H.; Nishimura, T.; Kobayashi, S.; 
Ozawa, T.; Kamada, N.; Komatsu, Y.; Kikuchi, S.; 
Oonota, H.; Kusama, H. Bioorg. Med. Chem. 2007, 
15, 868. (b) Mulvihill, M. J.; Ji, Q. S.; Werner, D.; 
Beck, P.; Cesario, C.; Cooke, A.; Cox, M.; Crew, 
A.; Dong, H.; Feng, L.; Foreman, K. W.; Mak, G.; 
Nigro, A.; O'Connor, M.; Saroglou, L.; Stolz, K. 
M.; Sujka, I.; Volk, B.; Weng, Q.; Wilkes, R. 
Bioorg. Med. Chem. Lett. 2007, 17, 1091. 
13 Noronha, G.; Barrett, K.; Cao, J.; Dneprovskaia, E.; 
Fine, R.; Gong, X.; Gritzen, C.; Hood, J.; Kang, X.; 
Klebansky, B.; Li, G.; Liao, W.; Lohse, D.; Mak, C. 
C.; McPherson, A.; Palanki, M. S. S.; Pathak, V. P.; 
Renick, J.; Soll, R.; Splittgerber, U.; Wrasidlo, W.; 
Zeng, B.; Zhao, N.; Zhou, Y. Bioorg. Med. Chem. 
Lett. 2006, 16, 5546. 
14 Nam, N. H.; Lee, S.; Ye, G.; Sun, G.; Parang, K. 
Bioorg. Med. Chem. 2004, 12, 5753. 
15 Boschelli, D. H.; Powell, D.; Golas, J. M.; 
Boschelli, F. Bioorg. Med. Chem. Lett. 2003, 13, 
2977. 
16 Vu, C. B.; Luke, G. P.; Kawahata, N.; Shakespeare, 
W. C.; Wang, Y.; Sundaramoorthi, R.; Metcalf, C. 
A.; Keenan, T. P.; Pradeepan, S.; Corpuz, E.; 
Merry, T.; Bohacek, R. S.; Dalgarno, D. C.; Narula, 
S. S.; van Schravendijk, M. R.; Ram, M. K.; 
Adams, S.; Liou, S.; Keats, J. A.; Violette, S. M.; 
Guan, W.; Weigele, M.; Sawyer, T. K. Bioorg. 
Med. Chem. Lett. 2003, 13, 3071. 
17 Jallal, H.; Valentino, M. -L.; Chen, G.; Boschelli, 
F.; Ali, S.; Rabbani, S. A. Cancer Res. 2007, 67, 
1580. 
18 Corless, C. L.; Fletcher, J. A.; Heinrich, M. C. J. 
Clin. Oncol. 2004, 22, 3813. 
19 Longley, D. B.; Johnston, P. G. J. Pathology 2005, 
205, 275. 
20 Shah, N. P.; Tran, C.; Lee, F. Y.; Chen, P.; Norris, 
D.; Sawyers, C. L. Science, 2004, 305, 399. 
21 Vultur, A.; Buettner, R.; Kowolik, C.; Liang, W.; 
Smith, D.; Boschelli, F.; Jove, R. Mol. Cancer Ther. 
2008, 7, 1185. 
22 Xu, W.; Doshi, A.; Lei, M.; Eck, M. J.; Harrison, S. 
C. Mol. Cell 1998, 3, 629. 
23 Schindler, T.; Sicheri, F.; Pico, A.; Gazit, A.; 
Levitzki, A.; Kuriyan, J. Mol. Cell, 1999, 3, 639. 
24 Zhu, X.; Kim, J. L.; Newcomb, J. R.; Rose, P. E.; 
Stover, D. R.; Toledo, L. M.; Zhao, H.; 
Morgenstern, K. A. Structure, 1999, 7, 651. 
25 (a) Kumar, A.; Wang, Y.; Lin, X.; Sun, G.; Parang, 
K. ChemMedChem 2007, 2, 1346. (b) Kumar, D.; 
Buchi Reddy, V.; Kumar, A.; Mandal, D.; Tiwari, 
R.; Parang, K. Bioorg. Med. Chem. Lett. 2011, 21, 
449. (c) Sharma, D.; Bhatia, S.; Sharma, R. K.; 
Tiwari, R.; Olsen, C. E.; Mandal, D.; Lehmann, J.; 
Parang, K.; Parmar, V. S.; Prasad, A. S. Biochimie 
2010, 92, 1164. (d) Tiwari, R.; Brown, A.; 
Narramaneni, S.; Sun, G.; Parang, K. Biochimie 
2010, 92, 1153. (e) Kumar, A.; Ye, G.; Wang, Y.; 
Lin, X.; Sun, G.; Parang, K. J. Med. Chem. 2006, 
49, 3395. (f) Nam, N.-H.; Ye, G.; Sun, G.; Parang, 
K. J. Med. Chem. 2004, 47, 3131.  
26 Hanefeld, U.; Rees, C. W. A.; White, J. P.; 
Williams, D. J. J. Chem. Soc. Perkin Trans. 1 1996, 
1545.  
27 Burchat, A. F.; Calderwood, D. J.; Friedman, M.  
M.; Hirst, G. C.; Li, B.; Rafferty, P.; Ritter, K.; 
Skinner, B. S. Bioorg. Med. Chem. Lett. 2002, 12, 
1687. 
28 Belches-Jablonski, A. P.; Biscardi, J. S.; Peavy, D. 
R.; Tice, D. A.; Romney, D. A.; Parsons, S. J. 
Oncogene, 2001, 20, 1465. 
29 Budde, R. J.; Ke, S.; Levin, V. A. Cancer 
Biochem. Biophys. 1994, 14, 171. 
